Celgene Corp. (CELG)

88.65
NASDAQ : Health Technology
Prev Close 88.65
Day Low/High 0.00 / 0.00
52 Wk Low/High 58.59 / 96.95
Avg Volume 9.78M
Exchange NASDAQ
Shares Outstanding 700.24M
Market Cap 63.30B
EPS 5.70
P/E Ratio 22.94
Div & Yield N.A. (N.A)

Latest News

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.

Lyfebulb And Celgene Announce Call For Innovation Challenge Applications To Address Unmet Needs In Multiple Sclerosis

Lyfebulb And Celgene Announce Call For Innovation Challenge Applications To Address Unmet Needs In Multiple Sclerosis

Applications to be accepted through Friday, April 12 at 11:59 p.m. EDT

Report Says Starboard Value Takes Stake in Bristol-Myers

Report Says Starboard Value Takes Stake in Bristol-Myers

Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.

Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns

Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns

Jim Cramer reacts to Starboard's stake in Bristol-Myers Squibb and Papa Johns.

Jim Cramer's Thoughts on Google, Starboard's Investments, and Tesla

Jim Cramer's Thoughts on Google, Starboard's Investments, and Tesla

Here's what Jim Cramer thinks about Google's earnings, Starboard's investments and Tesla's acquisition.

Jim Cramer: Tesla, Starboard and Google Earnings

Jim Cramer: Tesla, Starboard and Google Earnings

Jim Cramer weighs in on Starboard's investments, Tesla's purchase and Alphabet's earnings.

Starboard Value Snags Stake in Bristol-Myers Squibb, Says Bloomberg

Starboard Value Snags Stake in Bristol-Myers Squibb, Says Bloomberg

News follows Bristol-Myers Squibb's planned $74 billion buy of Celgene. TheStreet.com could not verify the report.

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

RMPIA soared 9.9% for the month, led by 11 double-digit gainers.

Wall Street Futures Mixed Amid 'Super Thursday' Earnings, 'Patient' Fed Tailwind

Wall Street Futures Mixed Amid 'Super Thursday' Earnings, 'Patient' Fed Tailwind

U.S. stocks look set for a mixed open Thursday, amid the busiest reporting session of the earnings season, even as global markets extend gains after the Federal Reserve signaled a pause in its rate hike plans and a series of blue-chip companies posted stronger-than-expected earnings and profit guidance that eased concerns over the prospect of a damaging slowdown in China.

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

Many see the Fed as done for the year. Never assume. Read the words as they are written.

Celgene Reports Fourth Quarter And Full Year 2018 Operating And Financial Results

Celgene Reports Fourth Quarter And Full Year 2018 Operating And Financial Results

Celgene Corporation (NASDAQ: CELG) reported operating results for the fourth quarter and full year of 2018.

Global Stocks Gain as 'Patient' Fed, Strong U.S. Earnings Keep Bulls in Charge

Global Stocks Gain as 'Patient' Fed, Strong U.S. Earnings Keep Bulls in Charge

Global stocks extended gains Thursday, with markets in Asia rising to the highest level in four months, after the U.S. Federal Reserve signaled a pause in its rate hike plans and a series of blue-chip companies posted stronger-than-expected earnings and profit guidance that eased concerns over the prospect of a damaging slowdown in China.

Bristol-Myers Tops Q4 Earnings, Pulls FDA Application for Cancer Combination

Bristol-Myers Tops Q4 Earnings, Pulls FDA Application for Cancer Combination

Bristol-Myers Squibb posts stronger-than-expected fourth-quarter earnings but pulls an application to the U.S. Food and Drug Administration for a blockbuster cancer drug combination in order to collect more data.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19)

New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19)

Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes. Plus, he's got your game plan.

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.

Jim Cramer: There's a Ton More Deals in the Pipe

Jim Cramer: There's a Ton More Deals in the Pipe

Deals that simply were unworkable four months ago because of price are now being done with alacrity.

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman is top of the heap for takeovers.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Try This Allergan Two-Week Setup

Try This Allergan Two-Week Setup

The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.

The Gold Rush of 2019

The Gold Rush of 2019

Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.

INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Recently Announced Merger

INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Recently Announced Merger

NEW YORK, Jan. 13, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: MINDBODY, Inc.

Pfizer and the Urge to Merge

Pfizer and the Urge to Merge

My stated reason for being in Pfizer all along has been price stability and income.

Some Early 2019 Market Observations

Some Early 2019 Market Observations

I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.

TheStreet Quant Rating: C+ (Hold)